23rd International AIDS Conference (AIDS 2020) Virtual

First case of long-term chronic HIV-1 remission without myeloablation

Roshini Claire Anthony, 20201001190001

A single case of a patient in Brazil has suggested that long-term suppression of chronic HIV may be possible without myeloablation, according to a presentation at AIDS 2020.

Recycling tenofovir better than zidovudine switch for HIV

Elvira Manzano, 20200901144500

Recycling tenofovir after failure of first-line treatment vs switching to second-line zidovudine is associated with better care retention, adherence, and viral load suppression in HIV patients, especially when combined with atazanavir boosted with ritonavir, a new study presented at AIDS 2020 Virtual has shown.

ADVANCE update: TAF/FTC + DTG regimen comparable to SoC for HIV-1 viral suppression

Roshini Claire Anthony, 20200827200001

HIV-1 RNA viral suppression is comparable between tenofovir alafenamide (TAF)/emtricitabine (FTC) + dolutegravir (DTG), tenofovir disoproxil fumarate (TDF)/FTC + DTG, and TDF/FTC/efavirenz (EFV) regimens, according to updated results of the ADVANCE trial.

Dolutegravir remains noninferior to low-dose efavirenz for HIV-1 after 96 weeks

Audrey Abella, 20200819100000

A dolutegravir-based regimen continued to show noninferiority to a low-dose efavirenz-based regimen after 96 weeks for the initial treatment of HIV-1 infection, according to the updated results of the NAMSAL* trial presented at AIDS 2020.

Single-tablet D/C/F/TAF regimen measures up even in HIV+ people with NPCs

Single-tablet D/C/F/TAF measures up in HIV+ people with comorbidities

Pearl Toh, 20200817140010

The once-daily single-tablet combination therapy comprising darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) yields high virologic response rates over 96 weeks in patients with HIV-1, regardless of the presence of neurologic and/or psychiatric comorbidities (NPCs), a subgroup analysis presented at the AIDS 2020 virtual conference has shown.

Hormonal contraceptive + TDF-based ART a recipe for bone disaster in young HIV+ women?

Audrey Abella, 20200814100000

The concomitant use of depot medroxyprogesterone acetate (DMPA) in young women with HIV initiating an antiretroviral therapy (ART) regimen containing tenofovir disoproxil fumarate (TDF) may lead to worsening of bone mineral density (BMD) loss, data presented at AIDS 2020 have shown.

Single-tablet regimen boosts virologic response in acute/early HIV-1 infection

Elaine Soliven, 20200814000000

Rapid treatment initiation with a single-tablet regimen comprising darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) demonstrated a high virological response rate in patients with acute or early HIV-1* infection, according to a subgroup analysis of the DIAMOND** study presented at AIDS 2020.

Switching to B/F/TAF combo maintains viral suppression in elderly with HIV

Switching to B/F/TAF maintains viral suppression in HIV+ elderly

Pearl Toh, 20200813150010

Switching to a single-tablet triple-drug combination comprising bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is well tolerated while continuing to provide virologic suppression through to 48 weeks in elderly people (aged ≥65 years) living with HIV (PLWH), shows a pooled analysis presented at the AIDS 2020 virtual conference.

Switching from EFV/FTC/TDF to BIC/FTC/TAF maintains virologic suppression in people living with HIV

Elaine Soliven, 20200811000000

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

Cabotegravir superior to TDF/FTC for HIV prevention

Stephen Padilla, 20200810120000

Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.